226 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28613895	66	A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.	Eli Lilly
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
27914947	11	Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).	University of Florence
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
27739691	7	Fragment-to-Lead Medicinal Chemistry Publications in 2015.	Astex Pharmaceuticals
26881908	13	De Novo Design at the Edge of Chaos.	Swiss Federal Institute of Technology (Eth)
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26288689	37	Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).	Glaxosmithkline
26263024	47	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.	Universit£
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25725607	15	2-Benzisothiazolylimino-5-benzylidene-4-thiazolidinones as protective agents against cartilage destruction.	University of Catania
25415648	63	Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.	Eli Lilly
25330343	49	Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.	Translational Research Institute
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24735644	19	Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.	University of Lille
23376997	53	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.	Universit£
23353736	41	Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).	Second Military Medical University
23287054	46	Sulphonamides: Deserving class as MMP inhibitors?	Indian Institute of Technology (Bhu)
23458498	24	Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.	Universit£
23246356	52	MMP inhibition by barbiturate homodimers.	Trinity College
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
21669521	44	Selective non zinc binding inhibitors of MMP13.	Astrazeneca
12217355	39	Analogue based design of MMP-13 (Collagenase-3) inhibitors.	Gvk Biosciences
22891645	83	Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).	Glaxosmithkline
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University of Technology
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
22540974	67	A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.	University Hospital M£Nster
22658537	76	Natural products as a gold mine for selective matrix metalloproteinases inhibitors.	East China University of Science and Technology
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
18358729	31	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.	Florida Atlantic University
19095454	63	Current perspective of TACE inhibitors: a review.	The M. S. University of Baroda
17981034	51	1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.	Johnson & Johnson Pharmaceutical Research and Development
17980583	46	Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).	Johnson & Johnson Pharmaceutical Research and Development
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University of Jerusalem
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research and Development
17956082	86	Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.	University Hospital of The Westf£Lische Wilhelms-Universit£T M£Nster
15214773	76	Fragment-based drug discovery.	Sunesis Pharmaceuticals
12930146	170	Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.	Institut De Recherches Servier
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
12773041	119	Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
10649971	180	Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.	Parke-Davis Pharmaceutical Research
10882358	62	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.	F. Hoffmann-La Roche
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
12824028	75	Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.	Pfizer
11677139	92	The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.	Wyeth-Ayerst Research
11591510	57	alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.	Pfizer
11206468	24	Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
11206467	44	The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.	Wyeth-Ayerst Research
11514167	88	The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.	Wyeth-Ayerst Research
11133099	43	Synthesis and activity of selective MMP inhibitors with an aryl backbone.	Pharmacia
10397503	40	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.	Universit£
9873598	39	The synthesis and biological activity of a novel series of diazepine MMP inhibitors.	Wyeth-Ayerst Research
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22118188	50	A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.	University Hospital M£Nster
22153941	140	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.	Astrazeneca
22018790	9	Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.	Scripps Florida
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22153340	37	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).	Pfizer
22088955	33	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.	Universit£
21937229	82	Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.	Novartis Institutes For Biomedical Research
21925881	60	Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.	Johnson & Johnson Pharmaceutical Research & Development
21982494	75	Continued exploration of biphenylsulfonamide scaffold as a platform for aggrecanase-1 inhibition.	Pfizer
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21536437	219	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.	Astrazeneca
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21493063	67	MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
21300546	129	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.	Astrazeneca
20965620	50	Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).	Protera
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20675133	32	SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.	Boehringer Ingelheim Pharmaceuticals
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19899765	69	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.	Cea
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19625186	59	3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.	Wyeth Research
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
19410464	71	Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.	Wyeth Research
19329309	49	Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.	Wyeth Research
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
19042129	4	Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13.	Stony Brook University
18974001	72	N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2).	Wyeth Research
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
18364257	16	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.	The Scripps Research Institute
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
18083558	112	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.	Johnson & Johnson Pharmaceutical Research and Development
18029177	57	A novel series of highly selective inhibitors of MMP-3.	Pfizer
17935984	29	Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.	Pfizer
17591762	102	Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.	Pfizer
17576061	132	Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17531482	67	Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.	Wyeth Research
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17267227	12	Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.	Clermont Auvergne University
17188863	107	Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
17027261	153	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
16942871	38	Potent, selective pyrimidinetrione-based inhibitors of MMP-13.	Pfizer
16723229	108	Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.	Wyeth Research
16632358	68	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.	Johnson & Johnson Pharmaceutical Research and Development
16516469	39	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.	Novartis Institutes For Biomedical Research
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16426848	80	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.	Wyeth Research
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16289878	35	Conversion of potent MMP inhibitors into selective TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16084720	83	Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.	Wyeth Research
16002291	24	Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.	Pfizer
15911259	49	Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.	Pfizer
15908214	95	Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.	Bristol-Myers Squibb Pharmaceutical Research Institute
15780611	74	Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.	Pfizer
15745814	75	Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.	Wyeth Research
15686921	55	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).	Pharmaceutical Research Institute
15566296	142	Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.	Wyeth Research
15357971	228	Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer
15261259	48	Benzodiazepine inhibitors of the MMPs and TACE. Part 2.	Wyeth Research
15125955	84	Reverse hydroxamate-based selective TACE inhibitors.	Kaken Pharmaceutical
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University of Athens
12951101	79	Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.	Pfizer
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12873518	81	Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.	Wyeth Research
12798337	6	Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.	Indiana University School of Medicine
12668018	138	Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.	Wyeth-Ayerst Research
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
12270165	80	Benzodiazepine inhibitors of the MMPs and TACE.	Wyeth Research
11934588	69	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.	Wyeth-Ayerst Research
11934587	19	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.	Wyeth-Ayerst Research
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11591509	46	alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.	Pfizer
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11563922	147	Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.	UniversitäT Bielefeld
11543676	45	Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.	Université
11543675	104	N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.	Université
11454461	111	The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.	Procter and Gamble Pharmaceuticals
11384231	26	2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.	F. Hoffmann-La Roche
11354379	37	Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.	Pfizer
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
11297453	173	Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.	Procter and Gamble Pharmaceuticals
11266157	12	Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.	University of Florida
31874775	176	Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.	"A. Moro" University of Bari
11229774	40	Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).	Pfizer
11212095	65	General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.	Institut De Recherches Servier
11150165	228	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.	Procter and Gamble Pharmaceuticals
32379447	44	Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF	Westf£Lische Wilhelms-Universit£T M£Nster
10915056	8	Difluoroketones as inhibitors of matrix metalloprotease-13.	Pfizer
10882354	19	Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.	Pfizer
27194201	164	Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.	Eli Lilly
30688452	94	Synthesis and Structural/Functional Characterization of Selective M14 Metallocarboxypeptidase Inhibitors Based on Phosphinic Pseudopeptide Scaffold: Implications on the Design of Specific Optical Probes.	Universitat Aut£Noma De Barcelona
10669564	189	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
10639284	119	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.	University of Florida
10522712	109	The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.	British Biotech Pharmaceuticals
30954331	54	Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.	University of Hamburg
10406637	20	Synthesis and identification of conformationally constrained selective MMP inhibitors.	Searle Discovery Research
10230616	30	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.	Searle Discovery Research
10021913	42	Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.	Pfizer
30846252	23	Recent developments in the synthesis and applications of phosphinic peptide analogs.	Wroclaw University of Technology
26810711	30	Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.	Westf£Lische Wilhelms-Universit£T
24355348	1	4-Thiazolidinones: the advances continue?.	Institute of Technology
23899323	87	Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.	University Hospital M£Nster
28818461	67	Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.	Nestl�
29191557	10	Synthesis of radioiodinated probes targeted toward matrix metalloproteinase-12.	Kobe Pharmaceutical University
30249495	241	Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.	Graz University of Technology
28626528	10	Exploitation of Conformational Dynamics in Imparting Selective Inhibition for Related Matrix Metalloproteinases.	University of Notre Dame
27996256	4	Zinc-Metalloproteinase Inhibitors: Evaluation of the Complex Role Played by the Zinc-Binding Group on Potency and Selectivity.	Universit£
28850227	85	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.	St. John'S University
28953404	70	Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.	Zhaw Zurich University of Applied Sciences
28558971	38	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.	Merck
28408220	55	First insight into structure-activity relationships of selective meprin? inhibitors.	Fraunhofer Institute For Cell Therapy and Immunology Izi
28653849	67	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.	Scripps Florida
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
16206837	9	Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.	University of Karachi
11916140	21	Carbonic anhydrase activity modulators: synthesis of inhibitors and activators incorporating 2-substituted-thiazol-4-yl-methyl scaffolds.	UniversitÀ
9463476	21	DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.	Suntory Institute For Bioorganic Research
9353361	3	[3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits.	National Institute of Diabetes and Digestive and Kidney Diseases
8632342	110	Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.	Eli Lilly
8358562	29	Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain.	Glaxo Group Research
7651361	32	Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.	Georgetown University
7515823	54	Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.	Novo Nordisk
7509389	8	Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	Fujisawa Pharmaceutical
18355729	12	Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin.	University of Dundee
19345579	14	Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.	Wyeth Research